Transcriptional Signatures Sensitive to Cognition-Improving Pharmacological Treatments in Fragile X Syndrome

This team is defining Fragile X “molecular signatures” to use as biomarkers. They’ll test CBD and other drugs in mice and compare findings to human brain data.

Read More »
Andres Ozaita, PhD

Targeting the Endocannabinoid System in Adult Fragile X Mice

CB1 blockade with rimonabant reversed cognitive, sensory, and seizure symptoms in FXS mice, highlighting the endocannabinoid system as a therapeutic target.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (40)